Modern epigenomics includes the quantitative determination of genome-wide DNA methylation and non-coding RNA expression, and analyzes structure and modifications of the chromatin. Functional studies of genetic and epigenetic regulation complement these profiling approaches.
The Plass group has gained international recognition for the establishment and improvement of the method of 'Restriction Landmark Genomic Scanning' (RLGS), which is a combination of methylation-sensitive restriction digestion of genomic DNA and two-dimensional gel electrophoresis (Plass et al., Oncogene 1999; Costello et al., Nat. Genet. 2000).
In order to keep pace with recent methodologic developments, we successively replaced RLGS by array- and next generation sequencing-based detection technologies. 'Methyl-CpG immunoprecipitation' enables array- or sequencing-based analysis of enriched methylated DNA (MCIp-CpG island array, MCIp-Seq) (Gebhard et al., Cancer Res. 2006). The Illumina 450k bead chip array platform provides quantitative methylation data for about 450.000 preselected CpG sites across the human genome. We have established 'Tagmentation-based whole genome bisulfite sequencing' (TB-WGBS)(Adey & Shendure, Genome Res. 2012; Lu et al., Epigenomics 2015) to interrogate the quantitative methylation states of all CpGs in human, mouse or other genome from less than 1,000 cells (Wang et al., Nat. Protoc. 2013). In addition, we apply the 'Assay for Transposase-Accessible Chromatin' (ATAC) (Buenrostro et al., Nat. Meth. 2013) and chromatin immunoprecipitation (ChIP) to analyze chromatin structure and modifications. To relate epigenomic alterations with expression changes, next generation-based transcriptome analysis is used to quantitatively analyze expression of mRNA, micro RNA and long-non coding RNA.
